pubmed.ncbi.nlm.nih.gov

Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse - PubMed

Review

Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse

Bronwyn M Kivell et al. Adv Pharmacol. 2014.

Abstract

Acute activation of kappa-opioid receptors produces anti-addictive effects by regulating dopamine levels in the brain. Unfortunately, classic kappa-opioid agonists have undesired side effects such as sedation, aversion, and depression, which restrict their clinical use. Salvinorin A (Sal A), a novel kappa-opioid receptor agonist extracted from the plant Salvia divinorum, has been identified as a potential therapy for drug abuse and addiction. Here, we review the preclinical effects of Sal A in comparison with traditional kappa-opioid agonists and several new analogs. Sal A retains the anti-addictive properties of traditional kappa-opioid receptor agonists with several improvements including reduced side effects. However, the rapid metabolism of Sal A makes it undesirable for clinical development. In an effort to improve the pharmacokinetics and tolerability of this compound, kappa-opioid receptor agonists based on the structure of Sal A have been synthesized. While work in this field is still in progress, several analogs with improved pharmacokinetic profiles have been shown to have anti-addictive effects. While in its infancy, it is clear that these compounds hold promise for the future development of anti-addictive therapeutics.

Keywords: Addiction; Drug abuse; Kappa-opioid receptor; Salvia divinorum; Salvinorin A.

© 2014 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare

Figures

Figure 1
Figure 1. Kappa opioid receptor agonists

Opioid receptor binding ([3H] U69,593) in CHO cells expressing human KOP receptors (Ki ±SD nM). ED50 = effective dose for 50% of maximal response in [35S] GTP-γS binding. Data for EOM SalB, MOM SalB and β-Tetrahydropyran Sal B taken from Prevatt-Smith et al. (2011) and data for Sal A taken from Lozama et al. (2011) (Lozama, Cunningham, Caspers, Douglas, Dersch, Rothman et al., 2011).

Similar articles

Cited by

References

    1. Acri JB, Thompson AC, Shippenberg T. Modulation of pre- and postsynaptic dopamine D2 receptor function by the selective kappa-opioid receptor agonist U69593. Synapse. 2001;39(4):343–350. - PubMed
    1. Avidorreiss T, Zippel R, Levy R, Saya D, Ezra V, Barg J, Matusleibovitch N, Vogel Z. Kappa-opioid receptor-transfected cell-lines - Modulation of adenylyl-cyclase activity following acute and chronic opioid treatments. Febs Letters. 1995;361(1):70–74. - PubMed
    1. Baker LE, Panos JJ, Killinger BA, Peet MM, Bell LM, Haliw LA, Walker SL. Comparison of the discriminative stimulus effects of Salvinorin A and its derivatives to U69,593 and U50,488 in rats. Psychopharmacology. 2009;203(2):203–211. - PubMed
    1. Beguin C, Potuzak J, Xu W, Liu-Chen L-Y, Streicher JM, Groer CE, Bohn LM, Carlezon WA, Jr, Cohen BM. Differential signaling properties at the kappa opioid receptor of 12-epi-Salvinorin A and its analogues. Bioorganic & Medicinal Chemistry Letters. 2012;22(2):1023–1026. - PMC - PubMed
    1. Belcheva MM, Clark AL, Haas PD, Serna JS, Hahn JW, Kiss A, Coscia CJ. mu and kappa opioid receptors activate ERK/MAPK via different protein kinase c isoforms and secondary messengers in astrocytes. Journal of Biological Chemistry. 2005;280(30):27662–27669. - PMC - PubMed

Publication types

MeSH terms

Substances